Figure 2From: Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone Imaging study with 18 F-FDG PET/CT. A: 18F-FDG PET/CT imaging studies at baseline, before administration of radium-223 (Ra-223) dichloride, B: 8F-FDG PET/CT imaging studies after 2 treatments with Ra-223 dichloride but before the third treatment.Back to article page